Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

Surrogate endpoints are frequently used as primary outcomes in clinical trials. This is appropriate when they are validated for their ability to predict clinical benefit measured on patient-relevant target outcome(s). Such validation is often lacking, thus increasing uncertainty in the decision-making process of regulatory bodies, health technology assessment agencies and payers. This ISPOR Task Force Report provides recommendations on best practices for surrogate endpoint evaluation for health technology assessment decision making. It covers methods that address the 3 levels of evidence for surrogate endpoint validation described in several methodological guidelines: (1) association between treatment effects on the surrogate and the target outcome, (2) association between the surrogate and the target outcome, and (3) biological plausibility. Statistical methods for surrogate endpoint evaluation include meta-analytic approaches using individual participant data or aggregate data. Multivariate meta-analytic models are recommended because they account for the within-study correlation and estimation errors. Issues with limited data and generalizability might be addressed through Bayesian approaches for information sharing from different treatments, treatment classes or indications. Real-world data can complement randomized controlled trial data, especially in rare diseases, but require careful consideration of underlying bias. For plausibility of health economic modeling, the surrogacy analysis and the health economic model should be aligned. The modeled time course of surrogate and target outcomes per treatment arm, as well as the modeled relative effects, should be reported to assess plausibility. Parameter and structural uncertainty in surrogate relationships can be explored through scenario analyses, probabilistic sensitivity analyses, value of information analyses, and threshold analysis techniques.

Authors

Institutions

Publication Details

Journal
Value in Health
Published
2026-02-01
DOI
https://doi.org/10.1016/j.jval.2026.01.020
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

Bart Heeg, Stephen Stefani, J. Kusel, O. Ciani et al.
Value in Health
Health Systems, Economic Evaluations, Quality of Life
article

Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

Bart Heeg, Stephen Stefani, J. Kusel, O. Ciani, Marc Buyse, Petros Pechlivanoglou, Sylwia Bujkiewicz, Wanrudee Isaranuwatchai, Dawn Lee, Mario Ouwens
article en

Abstract

Surrogate endpoints are frequently used as primary outcomes in clinical trials. This is appropriate when they are validated for their ability to predict clinical benefit measured on patient-relevant target outcome(s). Such validation is often lacking, thus increasing uncertainty in the decision-making process of regulatory bodies, health technology assessment agencies and payers. This ISPOR Task Force Report provides recommendations on best practices for surrogate endpoint evaluation for health technology assessment decision making. It covers methods that address the 3 levels of evidence for surrogate endpoint validation described in several methodological guidelines: (1) association between treatment effects on the surrogate and the target outcome, (2) association between the surrogate and the target outcome, and (3) biological plausibility. Statistical methods for surrogate endpoint evaluation include meta-analytic approaches using individual participant data or aggregate data. Multivariate meta-analytic models are recommended because they account for the within-study correlation and estimation errors. Issues with limited data and generalizability might be addressed through Bayesian approaches for information sharing from different treatments, treatment classes or indications. Real-world data can complement randomized controlled trial data, especially in rare diseases, but require careful consideration of underlying bias. For plausibility of health economic modeling, the surrogacy analysis and the health economic model should be aligned. The modeled time course of surrogate and target outcomes per treatment arm, as well as the modeled relative effects, should be reported to assess plausibility. Parameter and structural uncertainty in surrogate relationships can be explored through scenario analyses, probabilistic sensitivity analyses, value of information analyses, and threshold analysis techniques.

Value in Health
University of Leicester (GB), University of Exeter (GB), Health Intervention and Technology Assessment Program (TH), Hospital for Sick Children (CA), National Institute for Health and Care Excellence (GB), Department of Health (TW), Zorginstituut Nederland (NL), AstraZeneca (Switzerland) (CH), Grupo Hospitalar Conceição (BR), SickKids Foundation (CA), AstraZeneca (Sweden) (SE), Institute for Clinical Evaluative Sciences (CA), Impact (CA), Bocconi University (IT), Peninsula College of Medicine and Dentistry (GB), Hasselt University (BE), McMaster University (CA)
Peace, Justice and strong institutions
Openalex Percentile: Top 65%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.